Sunil Shah is the CEO of O2h. He was previously the Director of Business Development at Cambridge Biotechnology (now Biovitum). He has consulted into a range of biotechnology companies and major pharmaceuticals such as Pfizer, GSK, and BASF via Private consulting and the Life Sciences group of PA-Consulting. Prior to co-founding O2h, he was the co-founder and Director of a technology company. The Non Executive board positions he holds include those with Opal Drug Discovery Ltd and IOTA Pharmaceuticals Ltd. He holds an MBA from Cambridge University and a BSc in Biochemistry and is a member of the Royal Society of Chemistry.

Prashant Shah is the COO of O2h. He has consulted into the life science sector for companies such as GSK and a wide range of other sectors in the field of strategy, operations and finance. He worked in the strategy group of Accenture where he was awarded for thought leadership and then on private consulting engagements. Prior to co-founding O2h, he was the co-founder and Director of a technology company. He holds an MPhil in Management from Cambridge University, an MSc in Advanced Automation and Design from Cranfield University where he worked on the Human Genome Project and a BEng in Engineering & Operations Management from the University of Nottingham. He is also an Author.

Prof. Horwell graduated from London University before undertaking his PhD in organic heterocyclic chemistry at Leicester University with Prof. C W Rees, CBE, FRS. He then carried out post-doctoral research in Canada (National Research Council, Ottowa), Florida (Gainesville) and at Imperial College, London. This was followed by a research career in the pharmaceutical industry with Eli Lilly, Parke-David, Warner-Lambert and Pfizer. He has been a Visiting Professor at The University of East Anglia for over 10 years and accepted the appointment of Chair of Medicinal Chemistry in September 2001.

William is a scientist and entrepreneur. He has 15 years' experience in technology search, evaluation and implementation in life science companies, author of over 100 articles and 3 books. After an academic career in the UK and the USA, he joined PA Consulting Group in 1988, and Merlin Ventures as Head of Science in 1996. William founded Amedis Pharmaceuticals Ltd, developing new medicines from the application of organosilicon chemistry to drug discovery, and Delta G Ltd., a company exploring a 'systems biology' approach to diseases of energy metabolism. In 2003 he co-founded Choracle Ltd. to build software prediction of toxicity for medicine and chemicals development. William's expertise has been recognised with Toshiba Year of Invention prize in 1992, election to Human Genome Organisation in 1994, and appointment as a visiting Professor at Imperial College, London and a lecturer at Cambridge University.

Dr Keith Redpath has more than 20 years experience of the Life Science industry. His career started at Covance where he was responsible for the design and management of early-stage development programmes for pharmaceutical and biotechnology companies. Thereafter at PA Consulting he rose to the level of Partner and headed the Global Life Sciences practice. A spell in the City followed, where Keith built the Life Sciences equities research team of Panmure Gordon to one that was ranked in the top 10 in Europe. He was personally ranked second in the UK in 2004. His most recent position was as head of Life Sciences Research at Wood Mackenzie.

Martin Rigby is the CEO of ET Capital joined the the Cambridge office of 3i in 1986 as a specialist investor in start-up and early stage technology businesses. In 1992 he founded ETCapital Limited. He has made investments in nearly forty technology businesses over the past 17 years. He sits on the boards of six QTP investees, including: Bango.net, CellFactors, Impak, Oi! Bagel, Force12 and WAX info and is a non-executive director of the Cascade Seed Fund. He read history for his first degree at New College, Oxford, and was a regular army officer for seven years before completing an MBA at Cranfield University.

David has worked in the Pharmaceutical Industry for 25 years and brings a wealth of experience in the Preclinical, Early Clinical, and CMC aspects of Drug Development. Most recently he was the Senior Vice President for Technical Operations at Amicus Therapeutics, a clinical stage company located in New Jersey. Dr. Palling was heavily involved in the company’s start up in 2002 and subsequently was responsible for bringing it’s three products through IND-enabling studies and into Phase 1 clinical trials, using, in large part, the help of Contract Research Organizations. Prior to joining Amicus, Dr. Palling held a number of senior-level positions in drug development at J&J and Roche. Dr. Palling holds BSc and PhD degrees in Chemistry from the University of London and carried out Post-Doctoral Research in Biochemistry at Brandeis University in Waltham, MA.